Furthermore, we showed, using data from a nationwide prospective cohort study, that although early initiation of IL‐1–blocking therapy has improved the outcome for SD in general, the incidence of MAS in patients with sJIA‐SD treated with first‐line anakinra in the first two years post diagnosis does not seem to be meaningfully changed when compared to historic cohorts.17, 20, 27, 31, 32. Here, IL1B is linked to macrophage activation syndrome.